A new class-action Roundup lawsuit filed by 250 investors may be the only way to force Bayer to settle more Roundup cases in Phase 2. The latest verdict isn’t likely to impact future settlement amounts, as it is based on the facts of the Hardeman case. However, it does show that more litigation is likely. Here are some other facts you should know about the Roundup lawsuit. Read on to learn more about this new class-action case and the likely outcome.
The Roundup lawsuit is currently facing several hurdles.
The first is that Bayer and the plaintiffs’ lawyers accuse the company of cheating the settlement process. It’s not a surprise that the plaintiffs’ lawyers are worried about this; their clients are not. But the company should still be held accountable for its missteps, especially when it comes to the health of consumers. It’s important to note that the $10.9 billion settlement will not be final until Bayer has paid the entire amount.
In May, Bayer won its second Roundup trial. The jury in San Bernardino, California decided that the exposure to Roundup did not cause the child to develop non-Hodgkin’s lymphoma. While the ruling is not final, the plaintiff’s attorney is already planning an appeal, arguing that the case is not settled in the best interests of the plaintiff. The case was delayed for several weeks as Bayer and the plaintiffs’ lawyers tried to iron out settlement terms. On April 11, a decision was reached in a trial held over Zoom, which had numerous technical difficulties. After a long and complicated day of deliberation, the jury found that Bayer was not responsible for the child’s Burkitt’s lymphoma and that the family’s use of Roundup was not the sole cause.
Although the jury hasn’t reached a final decision on the case, it’s clear that the jury has found that Roundup has caused cancer in some people.
As a result, the jury awarded $78.5 million in damages. But a jury’s award of punitive damages isn’t final, and a judge can reduce this award by limiting the award. Nonetheless, the verdict is a major setback for Monsanto. It shows that the company is not only losing ground but that it is also losing credibility.
The Roundup lawsuit’s multi-district litigation is still undergoing a pause. The reason for the pause is that Bayer and the plaintiffs’ lawyers were working on terms of a settlement agreement. Despite these challenges, the $10.9 billion settlement will resolve most Roundup-related illness lawsuits. Meanwhile, plaintiffs’ attorneys say Bayer is reneging on its deal and the judge has expressed concerns about the company’s attempts to manipulate the settlement process.
Bayer may appeal this case. At this point, the Supreme Court has not agreed to hear the case.
Elizabeth Prelogar, the plaintiff’s attorney plans to file an appeal against the ruling. The lawsuit is currently pending, and Bayer has not yet announced its plans to appeal. A retrial in San Bernardino, California may be needed, but the San Bernardino jury’s decision is still a major setback for Roundup lawsuits.
The Roundup lawsuit is still ongoing. At the time of writing, over three hundred thousand people were notified of the lawsuit. The case was settled in November 2018. The judge awarded the plaintiffs more than 80 million dollars. It has also been noted that this case is a bellwether trial, as it was a “best-case scenario” case. It is the first of its kind in the world, proving that Roundup is a contaminant of food.
The San Bernardino jury’s ruling was not a good one for Bayer.
A majority of the court did not find a connection between Roundup and cancer. Moreover, the jury found that the exposure to the herbicide did not cause the plaintiff’s non-Hodgkin’s lymphoma. The verdict is a clear win for Bayer. If the jury agrees with this decision, it will be the first trial to be ruled on the Roundup product.
In a Roundup cancer lawsuit, Edwin Hardeman was awarded $80 million in damages. The case is a bellwether trial. This means that the case is used as a benchmark in other Roundup lawsuits. For the time being, the case will not be decided. If the judge finds it to be unsatisfactory, Bayer could appeal the verdict. In a trial, it is unlikely that the plaintiffs’ attorneys will win, but it could be the best chance they have of winning the lawsuit.
